Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein

label • the use of apixaban and dabigatran etexilate in young people under 18 in recommendation 1.11.9 was off label. See NICE's information on prescribing medicines. 1.11.8 Offer VTE prophylaxis to people undergoing elective knee replacement surgery whose VTE risk outweighs their risk of bleeding. Choose any one of: • Aspirin (75 mg or 150 mg) for 14 days. • LMWH for 14 days combined with anti-embolism stockings until discharge. • Rivaroxaban, which is recommended as an option in NICE technology appraisal guidance for preventing venous thromboembolism in adults after elective knee replacement surgery. For full details, see the guidance on rivaroxaban (TA170, 2009). [2018] 1.11.9 Consider one of the following if none of the options in recommendation 1.11.8 can be used: • Apixaban, which is recommended as an option in NICE technology appraisal guidance for preventing venous thromboembolism in adults after elective knee replacement surgery. For full details, see the guidance on apixaban (TA245, 2012). • Dabigatran etexilate, which is recommended as an option in NICE technology appraisal guidance for preventing venous thromboembolism in adults after elective knee replacement surgery. For full details, see the guidance on dabigatran etexilate (TA157, 2008). [2018] 1.11.10 Consider intermittent pneumatic compression if pharmacological
